Revolo Biotherapeutics, a company developing therapies that reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic diseases, has entered into a Master Service Agreement with CordenPharma, for the production of Revolo Bio’s first-in-class peptide and immune system resetting drug product, ‘1104, to support upcoming Phase 2 clinical trials in patients with eosinophilic esophagitis (EoE) and allergic disease.   CordenPharma is fully equipped to manu...